Skip to main content
. Author manuscript; available in PMC: 2022 Oct 10.
Published in final edited form as: Leuk Lymphoma. 2022 Jun 14;63(10):2403–2412. doi: 10.1080/10428194.2022.2084729

Figure 1.

Figure 1.

Study design. 234 consecutive patients with newly diagnosed or relapsed/refractory MM were admitted to the Dana Farber Cancer Institute/Brigham and Women’s Hospital inpatient wards for ASCT between June 2012 and April 2014. From this cohort, we excluded patients who had concomitant POEMS syndrome (n = 1), AL amyloidosis (n = 6), had a prior ASCT (n = 2), or who were admitted for a syngeneic or allogeneic stem cell transplant (n = 1) or tandem ASCT (n = 2). Of these 222 patients, 51 patients were found to have OH on the day of first orthostatic vitals check, making it impossible to distinguish whether these patients had preexisting or new-onset peri-transplant OH. These 51 patients were excluded and subsequent analyses were conducted on the remaining 171 patients.